Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 October 2023 | Story André Damons | Photo André Damons
Dr Asha Malan
Dr Asha Malan, Head of Vascular Surgery in the Faculty of Health Sciences at the University of the Free State (UFS), was elected as the President-elect for the Vascular Society of Southern Africa – the first woman in South Africa to be elected for this position in the Society’s 40-year existence.

Dr Asha Malan, the Head of Vascular Surgery in the Faculty of Health Sciences at the University of the Free State (UFS), has made history by being elected as the President-elect for the Vascular Society of Southern Africa. This milestone marks the first time a woman in South Africa has attained this prestigious position in the Society’s 40-year existence.

Dr Malan, an exemplary surgeon and a trailblazer, is not only one of the seven qualified female vascular surgeons in the country but also holds the distinction of being the youngest and first female to head an academic unit in South Africa. Her election took place at the recently concluded 2023 Vascular Society of Southern Africa (VASSA) Congress, a significant event for the UFS Division of Vascular Surgery, under her leadership as the congress chairperson. The Congress was hosted at the Lord Charles Hotel in Somerset West, Cape Town, in collaboration with the World Federation of Vascular Societies (WFVS) and the European Society of Vascular Surgery (ESVS).

Reflecting on her achievement, Dr Malan remarked, “It is not only an honour to be the first woman in 40 years to lead this Society, but an honour to be elected for this role.  VASSA has established a well-recognised international footprint and has invested significantly in promoting the growth of vascular surgery as a specialised surgical field in South Africa.” 

She added, “Representing the Society in this capacity allows me to continue serving its members and the Southern African community, creating awareness not only about the growing burden of vascular diseases but also the advancements in the field to address these challenges.” 

First gathering since 2018

The 2023 VASSA Congress marked the first gathering of Vascular Surgery specialists in South Africa since 2018, a gap caused by the pandemic. The event was attended by approximately 300 delegates, including nursing staff, radiographers, vascular technologists and other allied health professionals with a keen interest in Vascular Surgery. VASSA sponsored nursing staff, a radiographer and a vascular technologist from Universitas Academic Hospital to attend the meeting. 

The high-quality, four-day programme featured talks from local and international experts covering various aspects of vascular surgery, such as aortic surgery, peripheral arterial disease, carotid pathology, dialysis access and venous disease.  Notably, the academic programme saw the participation of 32 international speakers. Guest speaker, Dr Imtiaz Sooliman, the founder of the Gift of the Givers Foundation, delivered an inspiring talk during the ethics session titled “Humanitarian efforts within the Healthcare Sector – Sharing the Responsibility”.  

Presentations

During the Congress, Dr Malan and several Vascular Surgeons from the Department of Surgery represented the UFS. Dr Malan shared her experiences in developing a dedicated unit for the management of complex thoraco-abdominal aneurysmal disease, a talk that garnered significant interest and applause from both local and international experts. 

In her presentation, Dr Malan took the audience through her journey to several different international units to gain expertise in open thoraco-abdominal aortic surgery. She also highlighted the UFS Division of Vascular Surgery’s achievement of being the first academic Vascular Surgery unit in South Africa to perform a complex endovascular aortic aneurysm repair.  In addition, Dr Sam Letsoara and Dr Wikus Mulder, Vascular Surgery Fellows in training, presented the local evolution of endovascular therapy as well as an audit of endovascular management of blunt thoracic aortic injury at Universitas Academic Hospital, respectively.  Dr Sam Agbo, a registrar in the Department of Surgery, also presented his MMed research, evaluating the cost of open versus endovascular management of abdominal aortic aneurysms.

The Congress significantly contributed to the promotion of Vascular Surgical awareness and care, not only in South Africa, but across Africa and globally. It stands as a testament to the dedication and expertise of the Division of Vascular Surgery at the University of the Free State.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept